Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of VV913 capsules for premature ejaculation
CTR20262775Phase 2Active
- Sponsor
- Vigonvita Life Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VV913 in premature ejaculation (PE), sponsored by Vigonvita Life Sciences. Started Aug 2026; status: active.
02
Drugs
VV913
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on CTR20262775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262775.